 The FDA signed off Imara Incs NASDAQ: IMRA investigational new drug IND application for tovinontrine IMR-687 in heart failure with preserved ejection fraction HFpEF. The Company plans to initiate a Phase 2 trial in Q2 of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms. 